What do Hollywood celebrities have in common with snakebite victims? Recent research reveals that botulinum toxin, the active ingredient in the wrinkle smoother Botox, can be repurposed to block the paralyzing effects of viper venom. This represents the kind of dual-use opportunity the pharmaceutical industry loves to see: starting with a multibillion dollar cosmetic blockbuster and applying it to a neglected global health crisis. For SN, Jake Buehler explains how it works.

🐍 Blocking the bite

Snake bites lead to over 100,000 deaths annually, and many others experience permanent disfigurement such as loss of limbs and irreversible tissue death. In a stroke of biological irony, researchers showed that Botox’s paralyzing active ingredient suppressed inflammation and mitigated muscle tissue death in rabbits injected with viper venom. More research is needed before human testing, but this off-label application could in theory work in tandem with antivenoms, providing a crucial window of time for victims to reach a hospital, turning a disaster into a manageable medical event. What’s more, if the research were to inspire novel snakebite therapies, they could potentially cut “donor animals” needed to make antivenoms — such as horses, sheep and goats — out of the loop.

🤨 Beyond the brow

While Botox is the undisputed queen of the aesthetics market, its medical portfolio is surprisingly deep. It is currently the only treatment approved by the U.S. Food and Drug Administration for chronic migraines (a $1 billion+ subsector) and is widely used for overactive bladder, severe underarm sweating and other conditions. The pharmaceutical companies that make Botox and competitors proudly tout these myriad applications, so if testing were to pan out, we’d expect to see snakebite treatment listed among them.

👸🏼 The face of the market

The botulinum economy is dominated by a few heavy hitters who are aggressively expanding their medical indications:

• AbbVie (NYSE: ABBV) is the undisputed heavyweight champion after its $63 billion acquisition of Allergan. AbbVie owns the Botox brand and reported roughly $3.8 billion in Botox revenue for 2025 alone. AbbVie uses its aesthetic profits to fuel its massive R&D pipeline in oncology and immunology.
  
• Revance Therapeutics: The primary challenger with its long-lasting alternative, Daxxify. While smaller than AbbVie, they are gaining ground by offering a product that requires fewer injections per year than Botox. Revance reports annual revenues of $240 million.
  
• Galderma (SIX: GALD): This Swiss dermatology giant recently completed a massive IPO. They produce Dysport, a major Botox competitor used both cosmetically and for muscle spasticity. Galderma’s 2025 net sales topped $5 billion, with a strategy that combines skincare with prescription neuromodulators.

Get ready to watch Botox move from the vanity mirror to the emergency kit.

---

Disclaimer: The Science News Investors Lab newsletter is for informational purposes only and does not constitute investment advice. Society for Science and Science News Media Group assumes no liability for any financial decisions or losses resulting from the use of the content in this newsletter. Society for Science and Science News Media Group do not receive payments from, and do not have any ownership or investment interest in, the companies mentioned in this newsletter. Please consult a qualified financial advisor before making any investment decisions.